clinical trial · NCT06462469
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Steroid-refractory Acute Graft Versus Host DiseaseRuxolitinib
brief summary
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).
started
Jul 4, 2024
primary completion
Sep 24, 2026
completion
Jun 21, 2027
last updated
Aug 21, 2026
detailed description
Participants will start with a screening period to assess the eligibility; only participants who meet all the inclusion and none of the exclusion criteria will start study treatment from Day 1 to Week 24 or end of treatment. Following safety follow up visits, participants will receive the long-term follow-up until Month 12.
official title
A Single-arm, Multi-center Study of Ruxolitinib for the Treatment of Chinese Patients With Grade II-IV Corticosteroid-refractory Acute Graft Versus Host Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol